| Current and future pharmacological therapies for NAFLD/NASH |
91 |
| Evidence-based clinical practice guidelines for inflammatory bowel disease |
54 |
| Analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease |
40 |
| Clinical importance of IL-22 cascade in IBD |
35 |
| A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update |
31 |
| Differences in gut microbiota associated with age, sex, and stool consistency in healthy Japanese subjects |
26 |
| Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer |
25 |
| Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis |
25 |
| Sarcopenia in cirrhosis: from pathogenesis to interventions |
24 |
| Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection |
24 |
| Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth |
23 |
| Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis |
23 |
| Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease |
21 |
| Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis |
21 |
| Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods |
21 |
| New treatment options for inflammatory bowel diseases |
21 |
| Single cell analysis of Crohn's disease patient-derived small intestinal organoids reveals disease activity-dependent modification of stem cell properties |
18 |
| Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan |
17 |
| miR-324-3p promotes gastric cancer development by activating Smad4-mediated Wnt/beta-catenin signaling pathway |
17 |
| World trends for H-pylori eradication therapy and gastric cancer prevention strategy by H-pylori test-and-treat |
16 |
| The mesenchymal stem cell secretome as an acellular regenerative therapy for liver disease |
16 |
| Human hepatic stellate cell isolation and characterization |
16 |
| Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial |
15 |
| Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures |
15 |
| Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis |
14 |
| NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study |
14 |
| Gut microbiota dysbiosis worsens the severity of acute pancreatitis in patients and mice |
13 |
| NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir |
13 |
| The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study |
13 |
| Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese population |
13 |
| Nationwide survey for acute liver failure and late-onset hepatic failure in Japan |
12 |
| To die or not to die: death signaling in nonalcoholic fatty liver disease |
12 |
| The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection |
12 |
| Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study |
12 |
| A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation |
12 |
| Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping |
11 |
| Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science |
11 |
| Esophageal motility disorders: new perspectives from high-resolution manometry and histopathology |
11 |
| Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer |
10 |
| High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues |
10 |
| A scoring model for predicting advanced colorectal neoplasia in a screened population of asymptomatic Japanese individuals |
10 |
| Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group |
10 |
| Combination treatment with highly bioavailable curcumin and NQO1 inhibitor exhibits potent antitumor effects on esophageal squamous cell carcinoma |
10 |
| A novel urinary microRNA biomarker panel for detecting gastric cancer |
10 |
| Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials |
10 |
| Estimated prevalence of ulcerative colitis and Crohn's disease in Japan in 2014: an analysis of a nationwide survey |
9 |
| Bowel wall healing assessed using magnetic resonance imaging predicts sustained clinical remission and decreased risk of surgery in Crohn's disease |
9 |
| Clinicopathological features of superficial non-ampurally duodenal epithelial tumor; gastric phenotype of histology correlates to higher malignant potency |
9 |
| A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis |
9 |
| Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections |
9 |
